Expected Expansion of the Generic Drug Market
First written in FY2016. 17 of 37 entries say "Restated". Latest entry: 2026-10-14.
2 other companies' latest entry also says "Restated".
- 2026-10-14RestatedEarnings
「また、「経済財政運営と改革の基本方針2026（骨太の方針2026）」においても、後発医薬品の安定供給体制強化や産業構造改革の推進が示されており、後発医薬品製造基盤整備基金を活用した生産能力の増強、設備更新および品質保証体制の強化に向けた取り組みが進められております。」
後発医薬品の安定供給と産業構造改革に関する政策環境および対応の記載を継続している。 - FY2026AdvancedAnnual report
「The volume share reached 89.7% in the April 2025–March 2026 fiscal year, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals has continued to expand.」
The volume share of generic pharmaceuticals rose from the previously reported 86.5% to 89.7%, setting a new record for expansion in use. - FY2026-H1AdvancedAnnual report
「At the Health Insurance Subcommittee of the Social Security Council in September 2024, the Roadmap for Appropriate Use of Generic Pharmaceuticals Based on Ensuring Stable Supply was formulated. It set out a "primary target: a generic-pharmaceutical volume share of at least 80% in every prefecture by the end of fiscal 2029, while prioritizing the stable supply of pharmaceuticals" (carried over from the previous roadmap), and a "secondary target: a generic-pharmaceutical value share of at least 65% by the end of fiscal 2029."」
In addition to the previous volume-share target, it specifically describes the new roadmap's primary target of a volume share of at least 80% in every prefecture by the end of fiscal 2029 and secondary target of a value share of at least 65%. - FY2025AdvancedAnnual report
「The volume share reached 86.5% in the April 2024–March 2025 fiscal year, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals has continued to expand.」
It reports the new result of an 86.5% volume share for generic pharmaceuticals and presents a new roadmap targeting an 80% volume share and a 65% value share by the end of fiscal 2029. - FY2025-H1ReframedAnnual report
「In the pharmaceutical industry, government measures promoting the use of generic pharmaceuticals continue to advance, and from 1 October 2024, a system of selective coverage was introduced for long-listed products, meaning originator pharmaceuticals with generic alternatives. As patients will bear one-quarter of the difference in price from generic pharmaceuticals, the use of generic pharmaceuticals is expected to be promoted. Meanwhile, the Basic Policy on Economic and Fiscal Management and Reform 2024 states that, "with an eye to the ideal future of the generic pharmaceutical industry, structural reforms will be promoted, including industry realignment, and a legal framework for stable supply will be developed." It is expected that measures will be taken to eliminate shortages of generic pharmaceuticals and establish a supply structure capable of responding to continued use-promotion measures.」
While maintaining the outlook for market expansion driven by the promotion of generic use, it adds new policy elements, including selective coverage, elimination of supply shortages, structural reform with industry realignment in view, and a legal framework for stable supply. - FY2024AdvancedAnnual report
「The volume share reached 82.7% in the April 2023–March 2024 fiscal year, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals has continued to expand.」
The volume share of generic pharmaceuticals rose from the previously reported 80.7% to 82.7%, setting a new record for expansion in use. - FY2024-Q3RestatedAnnual report
「In the pharmaceutical industry, government measures promoting the use of generic pharmaceuticals are being advanced, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
It continues to describe a policy that prioritizes confidence in the quality and stable supply of generic pharmaceuticals, in addition to promoting their use. - FY2024-Q1RestatedAnnual report
「In the pharmaceutical industry, government measures promoting the use of generic pharmaceuticals are being advanced, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
It continues to describe a policy that prioritizes confidence in the quality and stable supply of generic pharmaceuticals and the promotion of their use. - FY2023AdvancedAnnual report
「The volume share reached 80.7% in the April 2022–March 2023 fiscal year, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals has continued to expand.」
The volume share of generic pharmaceuticals rose from the previously reported 79.5% to 80.7%, exceeding 80%. - FY2023-Q3RestatedAnnual report
「In the pharmaceutical industry, government measures promoting the use of generic pharmaceuticals are being advanced, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
It continues to describe a policy that prioritizes confidence in the quality and stable supply of generic pharmaceuticals and the promotion of their use. - FY2023-Q1RestatedAnnual report
「In the pharmaceutical industry, government measures promoting the use of generic pharmaceuticals are being advanced, and the Basic Policy on Economic and Fiscal Management and Reform 2021 sets out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
It continues to describe a policy that prioritizes confidence in the quality and stable supply of generic pharmaceuticals and the promotion of their use. - FY2022AdvancedAnnual report
「The volume share reached 79.5% in the April 2021–March 2022 fiscal year, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals has continued to expand.」
The volume share of generic pharmaceuticals rose from the previously reported 79.4% to 79.5%, representing a result close to the 80% target by September 2020. - FY2022-Q3RestatedAnnual report
「In the pharmaceutical industry, the Basic Policy on Economic and Fiscal Management and Reform 2021, approved by the Cabinet in June 2021, called for further promotion of generic use through measures including ensuring confidence in the quality and stable supply of generic pharmaceuticals, reviewing new targets, promptly making implementation status more transparent, including use rates by medical institutions and other entities to support insurers' efforts to ensure appropriate use, considering targets based on the healthcare-cost reduction effects of biosimilars, reviewing generic dispensing-system add-on payments in light of the new targets, and using formularies. It set out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
It continues to describe a policy promoting generic use, including confidence in the quality and stable supply of generic pharmaceuticals, transparency regarding usage, biosimilars, and formularies. - FY2022-Q2RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2021, approved by the Cabinet in June 2021, called for further promotion of generic use through measures including ensuring confidence in the quality and stable supply of generic pharmaceuticals, reviewing new targets, promptly making implementation status more transparent, including use rates by medical institutions and other entities to support insurers' efforts to ensure appropriate use, considering targets based on the healthcare-cost reduction effects of biosimilars, reviewing generic dispensing-system add-on payments in light of the new targets, and using formularies. It set out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
It continues to describe a policy promoting generic use, including confidence in quality and stable supply, transparency regarding usage, biosimilars, and formularies. - FY2022-Q1ReframedAnnual report
「In the pharmaceutical industry, the Basic Policy on Economic and Fiscal Management and Reform 2021, approved by the Cabinet in June 2021, called for further promotion of generic use through measures including ensuring confidence in the quality and stable supply of generic pharmaceuticals, reviewing new targets, promptly making implementation status more transparent, including use rates by medical institutions and other entities to support insurers' efforts to ensure appropriate use, considering targets based on the healthcare-cost reduction effects of biosimilars, reviewing generic dispensing-system add-on payments in light of the new targets, and using formularies. It set out a policy of ensuring confidence in the quality and stable supply of generic pharmaceuticals and promoting their use.」
The description has shifted from market expansion centered on the previous 80% volume-share target to a description centered on a new policy promoting use, including confidence in quality and stable supply, review of new targets, transparency regarding usage, biosimilars, and formularies. - FY2021-Q3AdvancedAnnual report
「The volume share reached 79.4% in the October–December 2020 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand.」
The volume share of generic pharmaceuticals rose from 78.9% in the previous quarter to 79.4%. - FY2021-Q2Volume share declined quarter on quarterAnnual report
「The volume share reached 78.9% in the July–September 2020 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand.」
While the volume share of generic pharmaceuticals declined from 79.3% in the previous quarter to 78.9%, the company explains that their use continues to expand. - FY2021-Q1AdvancedAnnual report
「The volume share reached 79.3% in the April–June 2020 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand.」
It states that the volume share of generic pharmaceuticals rose from 78.5% in the previous period to 79.3%, approaching the 80% target by September 2020. - FY2020AdvancedAnnual report
「The volume share reached 78.5% in the January–March 2020 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand.」
It states that the volume share of generic pharmaceuticals rose from 77.1% in the previous period to 78.5%, approaching the 80% target. - FY2020-Q3AdvancedAnnual report
「The volume share reached 77.1% in the October–December 2019 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand.」
The volume share of generic pharmaceuticals rose from 76.9% in the previous quarter to 77.1%. - FY2020-Q2AdvancedAnnual report
「The volume share reached 76.9% in the July–September 2019 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand. In addition, the Basic Policy on Economic and Fiscal Management and Reform 2019, approved by the Cabinet in June 2019, explicitly states that efforts will continue to achieve an 80% use rate for generic pharmaceuticals by September 2020, including stronger incentives, while ensuring stable supply and further strengthening confidence in quality.」
The volume share of generic pharmaceuticals rose from 75.8% in the previous period to 76.9%, and it adds the Basic Policy on Economic and Fiscal Management and Reform 2019's provisions concerning the government's target of an 80% use rate by September 2020, including stable supply, confidence in quality, and stronger incentives. - FY2020-Q1AdvancedAnnual report
「In the pharmaceutical industry, the Basic Policy on Economic and Fiscal Management and Reform 2017, approved by the Cabinet in June 2017, explicitly stated that "the use rate of generic pharmaceuticals shall be 80% by September 2020, and further measures to promote their use shall be considered so that this can be achieved as early as possible." Government policies promoting the use of generic pharmaceuticals have been implemented, and the volume share reached 75.8% in the April–June 2019 quarter, according to the Japan Generic Medicines Association, with the use of generic pharmaceuticals continuing to expand.」
It states that the volume share of generic pharmaceuticals reached 75.8%, up from the 75.7% reported for the previous period. - FY2019AdvancedAnnual report
「The volume share reached 75.7% in the January–March 2019 quarter, according to the Japan Generic Medicines Association, and the use of generic pharmaceuticals continues to expand.」
In connection with the government's 80% target, it newly states that the volume share of generic pharmaceuticals reached 75.7% in the January–March 2019 quarter. - FY2019-Q3RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2017, approved by the Cabinet in June 2017, explicitly stated that "the use rate of generic pharmaceuticals shall be 80% by September 2020, and further measures to promote their use shall be considered so that this can be achieved as early as possible," raising expectations for government policy support for generic use.」
It continues to describe the target of an 80% use rate for generic pharmaceuticals by September 2020 and expectations for policy support promoting their use. - FY2019-Q2SoftenedAnnual report
「In the pharmaceutical industry, the Basic Policy on Economic and Fiscal Management and Reform 2017, approved by the Cabinet in June 2017, explicitly stated that "the use rate of generic pharmaceuticals shall be 80% by September 2020, and further measures to promote their use shall be considered so that this can be achieved as early as possible," raising expectations for government policy support for generic use. However, policies to contain drug costs through drug-price reductions and other measures have also been indicated. In December 2017, the Central Social Insurance Medical Council approved the outline of reforms to the drug-pricing system, centered on conducting biennial drug-price revisions annually from fiscal 2021 and substantially reducing the prices of originator drugs for which generic alternatives are widely used, and the operating environment for the pharmaceutical industry is expected to become challenging.」
While maintaining expectations for policies promoting the use of generic pharmaceuticals, it adds the outlook for a more challenging industry environment due to drug-cost containment policies, including drug-price reductions, annual revisions from fiscal 2021, and substantial reductions in originator-drug prices. - FY2019-Q1SoftenedAnnual report
「Government policy support for the use of generic pharmaceuticals is expected, but competition has intensified as a result of the appropriate use of pharmaceuticals and the launch of authorized generics, particularly for major products. In addition, the fiscal 2018 medical fee revision was implemented in April 2018, and the impact on drug prices was a negative 7.48% on a drug-cost basis, making the domestic operating environment for the pharmaceutical industry challenging.」
While maintaining expectations for policies promoting generic use, it has added downside factors for the market outlook, including authorized-generic sales, more appropriate drug use, and the negative 7.48% impact on drug prices. - FY2018RestatedAnnual report
「The government has stated that it will set the use rate of generic pharmaceuticals at 80% by September 2020 and consider further measures to promote their use so that the target can be achieved as early as possible, and our group believes that the generic pharmaceutical market is on an expansionary trend.」
It continues to describe the government's target of an 80% use rate for generic pharmaceuticals by September 2020 and the expected market expansion. - FY2018-Q3RestatedAnnual report
「In the pharmaceutical industry, the Basic Policy on Economic and Fiscal Management and Reform 2017 (the so-called Honebuto Policy 2017), approved by the Cabinet in June 2017, explicitly stated that "the use rate of generic pharmaceuticals shall be 80% by September 2020, and further measures to promote their use shall be considered so that this can be achieved as early as possible," and the volume share of generic pharmaceuticals is expected to increase further going forward.」
It continues to describe the target of an 80% use rate for generic pharmaceuticals by September 2020 and the expected increase in their volume share. - FY2018-Q2RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2017 (the so-called Honebuto Policy 2017), approved by the Cabinet in June 2017, explicitly stated that "the use rate of generic pharmaceuticals shall be 80% by September 2020 (Heisei 32), and further measures to promote their use shall be considered so that this can be achieved as early as possible," and the volume share of generic pharmaceuticals is expected to increase further going forward.」
It continues to describe the target of an 80% use rate for generic pharmaceuticals by September 2020 and the expected increase in the generic market's volume share. - FY2018-Q1RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2017 (the so-called Honebuto Policy 2017), approved by the Cabinet in June 2017, explicitly stated that "the use rate of generic pharmaceuticals shall be 80% by September 2020 (Heisei 32), and further measures to promote their use shall be considered so that this can be achieved as early as possible," and the volume share of generic pharmaceuticals is expected to increase further going forward.」
It continues to describe the Honebuto Policy 2017 target of an 80% use rate for generic pharmaceuticals by September 2020 and the expected market expansion. - FY2017ReframedAnnual report
「The government has stated that it will set the use rate of generic pharmaceuticals at 80% by September 2020 (Heisei 32) and consider further measures to promote their use so that the target can be achieved as early as possible, and our group believes that the generic pharmaceutical market is on an expansionary trend.」
The description has been revised from the previous target of at least 70% by mid-2017 and at least 80% as early as possible between fiscal 2018 and fiscal 2020 to an 80% target by September 2020. - FY2017-Q3RestatedAnnual report
「Following the Ministry of Health, Labour and Welfare's publication in April 2013 of the Roadmap for Further Promoting the Use of Generic Pharmaceuticals, the Basic Policy on Economic and Fiscal Management and Reform 2015 (the so-called Honebuto Policy 2015), approved by the Cabinet in June 2015, explicitly stated that "the target volume share for generic pharmaceuticals shall be at least 70% by mid-2017 (Heisei 29), and at least 80% as early as possible between fiscal 2018 (Heisei 30) and the end of fiscal 2020 (Heisei 32)," and the volume share of generic pharmaceuticals is expected to increase further going forward.」
It continues to describe the government's target for the volume share of generic pharmaceuticals and the expected market expansion. - FY2017-Q2RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2015 (the so-called Honebuto Policy 2015), approved by the Cabinet in June 2015, explicitly stated that "the target volume share for generic pharmaceuticals shall be at least 70% by mid-2017 (Heisei 29), and at least 80% as early as possible between fiscal 2018 (Heisei 30) and the end of fiscal 2020 (Heisei 32)," and the volume share of generic pharmaceuticals is expected to increase further going forward.」
It continues to describe the government's target for the volume share of generic pharmaceuticals and the expected market expansion. - FY2017-Q1RestatedAnnual report
「The Basic Policy on Economic and Fiscal Management and Reform 2015 (the so-called Honebuto Policy 2015), approved by the Cabinet in June 2015, explicitly stated that "the target volume share for generic pharmaceuticals shall be at least 70% by mid-2017 (Heisei 29), and at least 80% as early as possible between fiscal 2018 (Heisei 30) and the end of fiscal 2020 (Heisei 32)," and the volume share of generic pharmaceuticals is expected to increase further going forward.」
It continues to describe the government's target for the volume share of generic pharmaceuticals and the expected market expansion. - FY2016First statedAnnual report
「The government set a new target of increasing the volume share of generic pharmaceuticals to "at least 70% by mid-2017 (Heisei 29), and at least 80% as early as possible from fiscal 2018 (Heisei 30) through fiscal 2020 (Heisei 32)."」
It cites the government's volume-share target as a premise for market expansion.